Literature DB >> 21471066

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky, David A Lynch, Jay H Ryu, Jeffrey J Swigris, Athol U Wells, Julio Ancochea, Demosthenes Bouros, Carlos Carvalho, Ulrich Costabel, Masahito Ebina, David M Hansell, Takeshi Johkoh, Dong Soon Kim, Talmadge E King, Yasuhiro Kondoh, Jeffrey Myers, Nestor L Müller, Andrew G Nicholson, Luca Richeldi, Moisés Selman, Rosalind F Dudden, Barbara S Griss, Shandra L Protzko, Holger J Schünemann.   

Abstract

This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format. For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak). Recommendations were based on majority vote. It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.

Entities:  

Mesh:

Year:  2011        PMID: 21471066      PMCID: PMC5450933          DOI: 10.1164/rccm.2009-040GL

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  313 in total

1.  Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C.

Authors:  Ramazan Idilman; Hülya Cetinkaya; Ismail Savaş; Nuray Aslan; Serpil Dizbay Sak; Mehmet Baştemir; Mustafa Sarioğlu; Irfan Soykan; Mithat Bozdayi; Alessandra Colantoni; Olcay Aydintuğ; Kadir Bahar; Ozden Uzunalimoğlu; David H Van Thiel; Numan Numanoğlu; Abdulkadir Dökmeci
Journal:  J Med Virol       Date:  2002-01       Impact factor: 2.327

2.  Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Fahad M Al-Hameed; Sat Sharma
Journal:  Can Respir J       Date:  2004-03       Impact factor: 2.409

3.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Sharon Safrin; Karen M Starko; Kevin K Brown; Paul W Noble; Ganesh Raghu; David A Schwartz
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

4.  The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study.

Authors:  G Raghu; Y N Mageto; D Lockhart; R A Schmidt; D E Wood; J D Godwin
Journal:  Chest       Date:  1999-11       Impact factor: 9.410

5.  Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure.

Authors:  J B Stern; H Mal; O Groussard; O Brugière; A Marceau; G Jebrak; M Fournier
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

6.  Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis.

Authors:  Jonathan Gribbin; Richard Hubbard; Chris Smith
Journal:  Respir Med       Date:  2008-12-06       Impact factor: 3.415

7.  Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.

Authors:  R W Tobin; C E Pope; C A Pellegrini; M J Emond; J Sillery; G Raghu
Journal:  Am J Respir Crit Care Med       Date:  1998-12       Impact factor: 21.405

8.  Inhalation of inorganic particles as a risk factor for idiopathic pulmonary fibrosis--elemental microanalysis of pulmonary lymph nodes obtained at autopsy cases.

Authors:  Hideya Kitamura; Shizuko Ichinose; Takumi Hosoya; Tsunehiro Ando; Soichiro Ikushima; Masaru Oritsu; Tamiko Takemura
Journal:  Pathol Res Pract       Date:  2007-06-25       Impact factor: 3.250

9.  Genetic studies in familial fibrosing alveolitis. Possible linkage with immunoglobulin allotypes (Gm).

Authors:  A W Musk; P J Zilko; P Manners; P H Kay; M I Kamboh
Journal:  Chest       Date:  1986-02       Impact factor: 9.410

10.  A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis.

Authors:  Brian G Kelly; She S Lok; Philip S Hasleton; Jim J Egan; James P Stewart
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

View more
  2000 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice.

Authors:  Shaik O Rahaman; Lisa M Grove; Sailaja Paruchuri; Brian D Southern; Susamma Abraham; Kathryn A Niese; Rachel G Scheraga; Sudakshina Ghosh; Charles K Thodeti; David X Zhang; Magdalene M Moran; William P Schilling; Daniel J Tschumperlin; Mitchell A Olman
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 3.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

4.  Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis.

Authors:  Xia Li; Chang Chen; Jinfu Xu; Jinming Liu; Xianghua Yi; Xiwen Sun; Jingyun Shi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 5.  Interstitial lung disease: the diagnostic role of bronchoscopy.

Authors:  Jad Kebbe; Tony Abdo
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study.

Authors:  Baruch Vainshelboim; Mordechai Reuven Kramer; Jonathan Myers; Avraham Unterman; Shimon Izhakian; Jose Oliveira
Journal:  Lung       Date:  2019-01-02       Impact factor: 2.584

7.  Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Authors:  Jennifer M Wang; Scott H Robertson; Ziyi Wang; Mu He; Rohan S Virgincar; Geoffry M Schrank; Rose Marie Smigla; Thomas G O'Riordan; John Sundy; Lukas Ebner; Craig R Rackley; Page McAdams; Bastiaan Driehuys
Journal:  Thorax       Date:  2017-08-31       Impact factor: 9.139

8.  VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis.

Authors:  Marianna Agassandian; John R Tedrow; John Sembrat; Daniel J Kass; Yingze Zhang; Elena A Goncharova; Naftali Kaminski; Rama K Mallampalli; Louis J Vuga
Journal:  Cell Signal       Date:  2015-09-18       Impact factor: 4.315

9.  CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep?

Authors:  Charalampos Mermigkis; Izolde Bouloukaki; Katerina M Antoniou; Demetrios Mermigkis; Kostas Psathakis; Ioannis Giannarakis; Georgios Varouchakis; Nikolaos Siafakas; Sophia E Schiza
Journal:  Sleep Breath       Date:  2013-02-06       Impact factor: 2.816

10.  Reference values for high attenuation areas on chest CT in a healthy, never-smoker, multi-ethnic sample: The MESA study.

Authors:  Imaani Easthausen; Anna Podolanczuk; Eric Hoffman; Steven Kawut; Elizabeth Oelsner; John S Kim; Ganesh Raghu; Karen Hinckley Stukovsky; Susan Redline; Robyn L McClelland; R Graham Barr; David J Lederer
Journal:  Respirology       Date:  2020-02-17       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.